|Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China's National Reimbursement Drug List (NRDL)|
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections
BOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China's National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country's National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), resulting in millions of patients gaining access to the broad-spectrum, once daily antibiotic.
"The addition of NUZYRA to China's NRDL means millions of patients now benefit from increased accessibility to this life-saving therapy for serious community-acquired infections, said Evan Loh, M.D., Paratek chief executive officer. "This NRDL listing expands China's antibiotic armamentarium to address antimicrobial resistance, an ever-growing, urgent, global public health crisis. We are grateful to the NHSA for their recognition of the clinical benefit and compelling value proposition that novel, innovative antibiotics such as NUZYRA provide to patients. We also applaud our partner Zai Lab for their commitment to bringing NUZYRA to patients in China."
NUZYRA was granted approval by the U.S. Food and Drug Administration in October 2018 and Paratek initiated the U.S. product launch in February 2019. Paratek's partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval of both IV and oral NUZYRA as a Category 1 innovative drug by the National Medical Products Administration (NMPA) of China for the treatment of CABP and ABSSSI in December 2021.
About Paratek Pharmaceuticals, Inc.
The company's lead commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.
Paratek is also conducting a Phase 2b study with NUZYRA in a rare disease, non-tuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States.
Paratek exclusively licensed U.S. rights and rights to the greater China territory for Seysara® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world. For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.
Forward Looking Statements
|1/18/2023 7:00:00 AM